Publicaciones en las que colabora con Antonio Rivero Juárez (8)

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2015

  1. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

2014

  1. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV

    The Lancet Infectious Diseases

  2. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients

    PLoS ONE, Vol. 9, Núm. 7

2013

  1. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

    Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653

  2. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

2012

  1. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

    AIDS, Vol. 26, Núm. 13, pp. 1721-1724

  2. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

    Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726